Jade Biosciences, Inc. (JBIO)
NASDAQ • Healthcare
Last close at September 14, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 12
in 58 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Jade Biosciences’ earnings missed expectations, with EPS of -$0.76 trailing the -$0.64 estimate by -$0.12, based on preliminary results for the second fiscal quarter of 2026 that were reported August 10, 2026. The biotechnology company generated a GAAP operating loss of about $58.9 million, and net income was a loss of roughly $55.8 million, down 73.5% from a loss of about $32.1 million a year ago. Cash burn remained evident, with negative operating cash flow of around $43.7 million during the quarter as the company continues advancing its kidney-disease pipeline, including lead program JADE-001 for IgA nephropathy alongside preclinical programs JADE-002 and JADE-003. Consensus for the next period calls for EPS of -$0.73.
About Jade Biosciences, Inc.
Jade Biosciences, Inc. is a NASDAQ-listed biotechnology company developing kidney-disease and earlier-stage therapeutic candidates. Trading as JBIO, the company is a small-cap healthcare name whose pipeline centers on JADE-001 for immunoglobulin A, or IgA, nephropathy, alongside two preclinical programs, JADE-002 and JADE-003.
Today's Snapshot
The session opened with JBIO slightly lower at 18.16, while its sector was flat.
Trading Volume
Below 10d avg (878.3K)
139.2K
vs S&P 500 Today
Strong Underperformance
-3.68%
Updated: September 15, 2026 at 15:03 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$17.53 - $20.55Sell
- RSI (14)30.66Neutral
- Stochastic %K (14, 3, 3)7.44Buy
- MACD Level (12, 26)-0.90Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.